Summary by Moomoo AI
CRISPR Therapeutics executive Samarth Kulkarni, who serves as both an officer and director, is set to sell 20,000 shares of common stock on January 16, 2024. The shares, valued at an aggregate market value of $1,250,056, were acquired on the same date through the exercise of stock options directly from the issuer. The transaction will be settled in cash. This planned sale follows a period where no securities transactions were reported by Kulkarni in the past three months, as per the latest filings.